CRISPR Therapeutics CRSP Foreign currency translation gains (losses)
Foreign currency translation gains (losses) at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's foreign currency translation gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's foreign currency translation gains (losses)?
- CRISPR Therapeutics (CRSP) reported foreign currency translation gains (losses) of -$32K in Q1 2026.
- How has CRISPR Therapeutics's foreign currency translation gains (losses) changed year-over-year?
- CRISPR Therapeutics's foreign currency translation gains (losses) decreased by 178.0% year-over-year, from $41K to -$32K.
- What is the long-term trend for CRISPR Therapeutics's foreign currency translation gains (losses)?
- Over 2 years (2023 to 2025), CRISPR Therapeutics's foreign currency translation gains (losses) has grown at a 14.3% compound annual growth rate (CAGR), from $72K to $94K.
- What does foreign currency translation gains (losses) mean?
- This represents the gains or losses resulting from the translation of financial statements of foreign subsidiaries into the reporting currency. It reflects the impact of exchange rate fluctuations on the value of international assets and liabilities. Monitoring this helps investors distinguish between operational performance and volatility driven by global currency markets.